United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medreich plc - cimetidine - oral tablet - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medreich plc - cimetidine - oral tablet - 800mg

United States - English - NLM (National Library of Medicine)

hospira, inc. - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - injection, solution - 6 mg in 1 ml - cimetidine hydrochloride injection is indicated in: (1) short-term treatment of active duodenal ulcer. most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see dosage and administration − duodenal ulcer). concomitant antacids should be given as needed for relief of pain. however, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) short-term treatment of active benign gastric ulcer. there is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) prevention of upper gastrointestinal bleeding in critically ill patients. (5) the treatment of pathological hypersecretory conditions

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - cimetidine 300 mg - cimetidine tablets usp are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see dosage and administration , duodenal ulcer ). concomitant antacids should be given as needed for relief of pain. however, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. - short-term treatment of active benign gastric ulcer. there is no information concerning usefulness of treatment periods of longer than 8 weeks. - erosive gastroesophageal reflux disease (gerd). erosive esophagitis diagnosed by endoscopy. treatment is indicated for 12 weeks for healing of

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - cimetidine 400 mg - cimetidine tablets usp are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see dosage and administration , duodenal ulcer ). concomitant antacids should be given as needed for relief of pain. however, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. - short-term treatment of active benign gastric ulcer. there is no information concerning usefulness of treatment periods of longer than 8 weeks. - erosive gastroesophageal reflux disease (gerd). erosive esophagitis diagnosed by endoscopy. treatment is indicated for 12 weeks for healing of

United States - English - NLM (National Library of Medicine)

carilion materials management - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - cimetidine 400 mg - cimetidine tablets usp are indicated in: cimetidine is contraindicated for patients known to have hypersensitivity to the product.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cimetidine 200mg;  ; cimetidine 200mg - film coated tablet - 200 mg - active: cimetidine 200mg   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: cimetidine 200mg excipient: colloidal silicon dioxide ferric oxide as croscarmellose sodium hypromellose macrogol 3350 magnesium stearate microcrystalline cellulose quinoline yellow titanium dioxide - conditions where the reduction of gastric acid secretion is beneficial e.g. treatment of duodenal and benign ulceration, gastro-oesophageal reflux disease, recurrent ulceration of the upper gastrointestinal tract, stomal ulceration, persistent non-ulcer dyspepsia and the short-term treatment of dyspepsia or pain associated with hyperacidity. prevention of the recurrence of duodenal or benign gastric ulcers in patients who have a history of recurrence or complications or for whom surgery is contraindicated. prevention of stress ulcer in patients at risk of haemorrhage, the management of pathological hypersecretion e.g. zollinger-ellison syndrome, systemic mastocytosis and multiple endocrine adenomas and the management of haemorrhage due to peptic ulceration or erosions of the upper gastrointestinal tract. reduction of gastric acidity and secretory volume thus reducing the risk of pulmonary damage from aspiration of gastric contents in patients undergoing general anaesthesia. cimetidine can be used in conjunction with a h1 antagonist for the prevention of anaphylactic reaction secondary to histamine release caused by infusion of certain medicines e.g. radiopaque contrast agents and plasma substitutes.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cimetidine 400mg;  ; cimetidine 400mg - film coated tablet - 400 mg - active: cimetidine 400mg   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: cimetidine 400mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose ferric oxide as macrogol 3350 magnesium stearate microcrystalline cellulose quinoline yellow titanium dioxide - conditions where the reduction of gastric acid secretion is beneficial e.g. treatment of duodenal and benign ulceration, gastro-oesophageal reflux disease, recurrent ulceration of the upper gastrointestinal tract, stomal ulceration, persistent non-ulcer dyspepsia and the short-term treatment of dyspepsia or pain associated with hyperacidity. prevention of the recurrence of duodenal or benign gastric ulcers in patients who have a history of recurrence or complications or for whom surgery is contraindicated. prevention of stress ulcer in patients at risk of haemorrhage, the management of pathological hypersecretion e.g. zollinger-ellison syndrome, systemic mastocytosis and multiple endocrine adenomas and the management of haemorrhage due to peptic ulceration or erosions of the upper gastrointestinal tract. reduction of gastric acidity and secretory volume thus reducing the risk of pulmonary damage from aspiration of gastric contents in patients undergoing general anaesthesia. cimetidine can be used in conjunction with a h1 antagonist for the prevention of anaphylactic reaction secondary to histamine release caused by infusion of certain medicines e.g. radiopaque contrast agents and plasma substitutes.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cimetidine -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cimetidine - oral tablet - 200mg